Newpharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Newpharma - overview
Established
2008
Location
Liege, -, Belgium
Primary Industry
Pharmaceuticals
About
Newpharma is an online pharmacy that specializes in providing a comprehensive selection of health and wellness products, including medications, supplements, and personal care items, effectively catering to diverse consumer needs in Europe. Founded in 2008 in Liege, Belgium, Newpharma operates as an online pharmacy offering an extensive range of health products. The company has undergone strategic pivots but details on specific changes are not provided. Newpharma has secured a total of EUR 72.
000 mn in funding, with the latest round being LP Direct, where Colruyt Group was an investor. It has completed three deals to date, with the founder's history not disclosed. Newpharma operates as a leading online pharmacy, providing a wide range of health and wellness products tailored to various consumer needs. The company's core offerings include over-the-counter medications, vitamins, dietary supplements, personal care items, and beauty products, all designed to support overall health and well-being.
Newpharma serves a diverse customer base that includes individual consumers seeking health solutions, as well as special categories such as pregnant women, seniors, and children. The online pharmacy also caters to pet owners with veterinary products. Newpharma primarily operates in the European market, with a significant presence in Belgium, and it ensures access to its products through a user-friendly digital platform that facilitates direct-to-consumer sales. Newpharma generated revenue of EUR 171,601,810.
4 in 2022, with an EBITDA of EUR -1,461,506. 3. The company earns its revenue through direct online sales of its extensive product offerings, which encompass a variety of health and wellness categories. Transactions typically occur through individual purchases made by consumers on their website, where they can select items from a broad catalog.
Newpharma has established a reputation for prompt delivery and discreet packaging, enhancing customer satisfaction and encouraging repeat purchases. In the future, Newpharma aims to enhance its product offerings by launching new health and wellness items, though specific details on product launches are not disclosed. The company is also planning to expand into new markets within Europe to broaden its customer base. The recent funding from the LP Direct round will be utilized to support these expansion initiatives.
Notably, Korys has exited its stake in Newpharma, with the financial terms of the deal undisclosed.
Current Investors
Korys, Colruyt Group
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
http://www.newpharma.be
Total Amount Raised
Subscriber access only
Newpharma - timeline of key events
Newpharma - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 14,646 | 8,741,326 | - | - | - | - | 63,355,923 | 81,771,132 | 95,333,769 | 145,123,311 | 154,002,066 | 162,841,137 | - | - | - |
| % Revenue Growth (YoY) | - | 59584.1% | - | - | - | - | - | 29.1% | 16.6% | 52.2% | 6.1% | 5.7% | - | - | - |
| EBITDA (USD) | (57,293) | 429,304 | 523,511 | 905,797 | 1,549,615 | 1,821,821 | 1,910,489 | 1,309,830 | 392,009 | (535,427) | 769,380 | (1,386,893) | - | - | - |
| Operating Income (USD) | (63,403) | 397,232 | 489,384 | 855,287 | 1,495,121 | 1,758,548 | 1,850,272 | 1,248,960 | 352,778 | (567,100) | 740,962 | (1,403,188) | - | - | - |
| Operating Margin | (432.9%) | 4.5% | - | - | - | - | 2.9% | 1.5% | 0.4% | (0.4%) | 0.5% | (0.9%) | - | - | - |
| % EBITDA Margin | (391.2%) | 4.9% | - | - | - | - | 3.0% | 1.6% | 0.4% | (0.4%) | 0.5% | (0.9%) | - | - | - |
| NET Income (USD) | (66,621) | 188,434 | 191,095 | 381,582 | 701,819 | 836,038 | 832,311 | 289,580 | (497,552) | (1,796,711) | (273,399) | (1,387,541) | - | - | - |
| % Net Margin | (454.9%) | 2.2% | - | - | - | - | 1.3% | 0.4% | (0.5%) | (1.2%) | (0.2%) | (0.9%) | - | - | - |
Newpharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Completed | Newpharma | - | ||||||||
| LP Direct | Completed | Newpharma | - | ||||||||
| Unspecified Exit | Completed | Newpharma | - |
Displaying 1 - 3 of 3
Newpharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.